Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to stop liver cancer recurrence after surgery

NCT ID NCT04102098

Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a combination of two drugs (atezolizumab and bevacizumab) can prevent liver cancer from returning in people who had surgery or ablation to remove their tumor. About 668 participants at high risk of recurrence were randomly assigned to receive the drug combination or just be monitored. The main goal was to see how long people stayed cancer-free.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

668 people

The number who actually took part.

Started

Dec 2019

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants with a first diagnosis of HCC who have undergone either a curative resection or ablation (radiofrequency ablation \[RFA\] or microwave ablation \[MVA\] only) within 4-12 weeks prior to randomization * Documented diagnosis of HCC that has been completely resected or ablated (RFA or MVA only) * Absence of major macrovascular invasion (except Vp1/Vp2) and extrahepatic spread * Absence of extrahepatic spread as confirmed by CT or MRI scan of the chest, abdomen, pelvis, and head prior to and following curative procedure * Full recovery from surgical resection or ablation within 4 weeks prior to randomization * High risk for HCC recurrence after resection or ablation * For patients who received post-operative transarterial chemoembolization: full recovery from the procedure within 4 weeks prior to randomization * For patients with resected HCC, availability of a representative baseline tumor tissue sample * ECOG Performance Status of 0 or 1 * Child-Pugh Class A status * Adequate hematologic and end-organ function * For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods * For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm Exclusion Criteria: * Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC * Evidence of residual, recurrent, or metastatic disease at randomization * Clinically significant ascites * History of hepatic encephalopathy * Prior bleeding event due to untreated or incompletely treated esophageal and/or gastric varices within 6 months prior to randomization * Have received more than 1 cycle of adjuvant TACE following surgical resection * Active or history of autoimmune disease or immune deficiency * History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan * Significant cardiovascular disease within 3 months prior to Day 1 of Cycle 1, unstable arrhythmia, or unstable angina * History of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death * Active tuberculosis * Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications * Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of atezolizumab or within 6 months after the final dose of bevacizumab. Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to Day 1 of Cycle 1. * Co-infection with HBV and HCV * Co-infection with HBV and hepatitis D viral infection * Clinical significant uncontrolled or symptomatic hypercalcemia * Any treatment for HCC prior to resection or ablation, including systemic therapy and locoregional therapy such as TACE * Treatment with systemic immunostimulatory or immunosuppressive agents * Inadequately controlled arterial hypertension * History of hypertensive crisis or hypertensive encephalopathy * Significant vascular disease * Evidence of bleeding diathesis or significant coagulopathy * Current or recent use of aspirin or full-dose oral or parenteral anticoagulants * Core biopsy within 3 days of Day 1 of Cycle 1 * History of GI fistula, GI perforation, or intra-abdominal abscess * Serious non-healing or dehiscing wound * Major surgical procedure within four weeks * Chronic daily treatment with a non-steroidal anti-inflammatory drug

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinoma, hepatocellular are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoma, hepatocellular

Contacts and locations

Locations

  • AZ Delta (Campus Rumbeke)

    Roeselare, 8800, Belgium

  • Adana Baskent University Hospital

    Adana, 01120, Turkey (Türkiye)

  • Affiliated Hospital of Bengbu Medical College

    Bengbu, 233004, China

  • Ajou University Medical Center

    Gyeonggi-do, 16499, South Korea

  • Anhui Province Cancer Hospital

    Hefei, 12345, China

  • Anhui Provincial Hospital

    Anhui, 230001, China

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Asst Santi Paolo E Carlo

    Milan, Lombardy, 20142, Italy

  • Auckland City Hospital

    Auckland, 1023, New Zealand

  • Azlenda Ospendaliero-Universitaria Pisana

    Pisa, Tuscany, 56100, Italy

  • Beijing Cancer Hospital

    Beijing, 100142, China

  • Boramae Medical Center

    Seoul, 07061, South Korea

  • CHA Bundang Medical Center

    Gyeonggi-do, 13496, South Korea

  • CHU Bordeaux - Hôpital Haut-Lévêque

    Pessac, 33604, France

  • CHU de Toulouse - Hôpital Rangueil

    Toulouse, 31059, France

  • Cancer Center of Guangzhou Medical University

    Guangzhou, 510000, China

  • Chang Gung Medical Foundation - Linkou

    Taoyuan, 333, Taiwan

  • Changhua Christian Hospital

    Chang-hua, 500, Taiwan

  • Chiang Rai Prachanukroh Hospital

    Chiang Rai, 57000, Thailand

  • Chiba University Hospital

    Chiba, 260-8677, Japan

  • Chulabhorn Hospital

    Lak Si, 10210, Thailand

  • Clinica CIMCA

    San José, 10103, Costa Rica

  • Clinical hospital #1, FBHI Volga district medical center, Federal Medical and Biological Agency

    Nizhny Novgorod, Niznij Novgorod, 603109, Russia

  • Clínica San Gabriel

    Lima, 15088, Peru

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Daping Hospital of Third Military Medical University

    Chongqing, 400042, China

  • Ehime Prefectural Central Hospital

    Ehime, 790-0024, Japan

  • Fakultni Thomayerova Nemocnice

    Prague, 140 59, Czechia

  • Fakultni nemocnice Brno

    Brno, 625 00, Czechia

  • Filios Alta Medicina

    Monterrey, Nuevo León, 64460, Mexico

  • First Moscow State Medical University n.a. I.M. Sechenov

    Moscow, Moscow Oblast, 119991, Russia

  • Fondation Hopital Saint Joseph

    Marseille, 13285, France

  • Fudan University Shanghai Cancer Center

    Shanghai, 200032, China

  • Fujian Cancer Hospital

    Fuzhou, 350014, China

  • Gangnam Severance Hospital

    Seoul, 06273, South Korea

  • Gordon & Leslie Diamond Health Care Centre

    Vancouver, British Columbia, V5Z 1M9, Canada

  • Group of companies "Medci"

    Moskva, Moscow Oblast, 105229, Russia

  • Guangxi Cancer Hospital of Guangxi Medical University

    Nanning, 530021, China

  • Harbin Medical University Cancer Hospital

    Harbin, 150081, China

  • Henry Ford Health System

    Detroit, Michigan, 48202, United States

  • Hiroshima University Hospital

    Hiroshima, 734-8551, Japan

  • Hopital Jean Minoz

    Besançon, 25030, France

  • Hopital Robert Debre

    Reims, 51092, France

  • Hopital de Pontchaillou

    Rennes, 35033, France

  • Hopitaux de Brabois - Gastro-Entereologie

    Vandœuvre-lès-Nancy, 54511, France

  • Hospital Alemao Oswaldo Cruz

    São Paulo, São Paulo, 01323-020, Brazil

  • Hospital General Universitario Gregorio Marañon

    Madrid, 28007, Spain

  • Hospital Sao Rafael - HSR

    Salvador, Estado de Bahia, 41253-190, Brazil

  • Hospital Universitario Infanta Cristina

    Badajoz, 06080, Spain

  • Hospital Universitario Puerta de Hierro

    Majadahonda, Madrid, 28222, Spain

  • Hospital do Cancer UOPECCAN

    Cascavel, Paraná, 85806-300, Brazil

  • Huashan Hospital Affiliated to Fudan University

    Shanghai, 200040, China

  • Hyogo Medical University Hospital

    Hyōgo, 663-8501, Japan

  • Hôpital Albert Michallon

    La Tronche, 38700, France

  • Hôpital Avicenne - Groupement Hospitalier Universitaire Paris Seine St Denis

    Bobigny, 93009, France

  • Imeldaziekenhuis

    Bonheiden, 2820, Belgium

  • Instituto Nacional de Enfermedades Neoplasicas

    Lima, 15038, Peru

  • Japanese Red Cross Musashino Hospital

    Tokyo, 180-8610, Japan

  • Japanese Red Cross Society Himeji Hospital

    Hyōgo, 670-8540, Japan

  • Kaiser Permanente Los Angeles

    Los Angeles, California, 90027, United States

  • Kanagawa Cancer Center

    Kanagawa, 241-8515, Japan

  • Kanazawa University Hospital

    Ishikawa, 920-8641, Japan

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, 807, Taiwan

  • Kindai University Hospital

    Osaka, 589-8511, Japan

  • Kitasato University Hospital

    Kanagawa, 252-0375, Japan

  • Klinik Johann Wolfgang von Goethe Uni

    Frankfurt am Main, 60590, Germany

  • Klinikum Klagenfurt am Wörtersee

    Klagenfurt, 9020, Austria

  • Klinikum der Uni Regensburg

    Regensburg, 93053, Germany

  • Kumamoto University Hospital

    Kumamoto, 860-8556, Japan

  • Kyungpook National University Hospital

    Daegu, 41944, South Korea

  • Lkh-Univ. Klinikum Graz

    Graz, 8036, Austria

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Maastricht University Medical Center

    Maastricht, 6229 HX, Netherlands

  • McGill University Health Centre - Glen Site

    Montreal, Quebec, H4A 3J1, Canada

  • Medizinische Universität Wien

    Vienna, 1090, Austria

  • Mengchao Hepatobiliary Hospital Of Fujian Medical University

    Fuzhou, 350025, China

  • Mercy Medical Center

    Baltimore, Maryland, 21202, United States

  • Nanfang Hospital, Southern Medical University

    Guangzhou, 510515, China

  • Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School

    Nanjing, 210029, China

  • Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie

    Warsaw, 02-034, Poland

  • National Cancer Centre

    Singapore, 168583, Singapore

  • National Taiwan Uni Hospital

    Taipei, 100, Taiwan

  • Northern Jangsu People's Hospital

    Yangzhou, China

  • Oaxaca Site Management Organization

    Oaxaca City, 68000, Mexico

  • Osaka Red Cross Hospital

    Osaka, 543-8555, Japan

  • Ospedale Maggiore Policlinico

    Milan, Lombardy, 20122, Italy

  • Ospedale Regionale Di Parma

    Parma, Emilia-Romagna, 43100, Italy

  • Peking Union Medical College Hospital

    Beijing, 100730, China

  • Prince of Wales Hospital

    Shatin, Hong Kong

  • Pusan National University Hospital

    Busan, 49241, South Korea

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • Rajavithi Hospital

    Bangkok, 10400, Thailand

  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, 200127, China

  • Renmin Hospital of Wuhan University

    Wuhan, 430060, China

  • Russian Scientific Center of Radiology and Surgical Technologies

    Pesochny, Sankt-Peterburg, 197758, Russia

  • Samsung Medical Center

    Seoul, 6351, South Korea

  • Sapporo Kosei General Hospital

    Hokkaido, 060-0033, Japan

  • Seoul National University Bundang Hospital

    Gyeonggi-do, 13620, South Korea

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Seoul St Mary's Hospital

    Seoul, 06591, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722, South Korea

  • Shandong Cancer Hospital

    Jinan, 250117, China

  • Shengjing Hospital of China Medical University

    Shenyang, 110004, China

  • Siriraj Hospital

    Bangkok, 10700, Thailand

  • Sociedade beneficente de senhoras Hospital Sirio Libanes

    Brasília, Federal District, 70200-730, Brazil

  • St Vincent's Hospital Sydney

    Darlinghurst, New South Wales, 2010, Australia

  • Sun Yet-sen University Cancer Center

    Guangzhou, 510060, China

  • Swedish Cancer Inst.

    Seattle, Washington, 98104, United States

  • Taipei Veterans General Hospital

    Taipei, 112, Taiwan

  • Tan Tock Seng Hospital

    Singapore, 308433, Singapore

  • The 81st Hospital of P.L.A.

    Nanjing, 210002, China

  • The First Affiliate Hospital of Guangxi Medical University

    Nanning, 530021, China

  • The First Affiliated Hospital of China Medical University

    Shenyang, 110001, China

  • The First Hospital of Jilin University

    Changchun, 130021, China

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, 230601, China

  • The Second Affiliated Hospital of Dalian Medical University

    Dalian, 116027, China

  • The Tumor Hospital of Xinjiang Medical University

    Ürümqi, 830000, China

  • The University of Texas Southwestern Medical Center at Dallas

    Dallas, Texas, 75390, United States

  • The University of Tokyo Hospital

    Tokyo, 113-8655, Japan

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

  • Tianjin Cancer Hospital

    Tianjin, 300060, China

  • Tokushima University Hospital

    Tokushima, 770-8503, Japan

  • Toranomon Hospital

    Tokyo, 105-8470, Japan

  • Ulsan University Hosiptal

    Ulsan, 44033, South Korea

  • Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik I.

    Bonn, 53127, Germany

  • Universitätsklinikum Ulm

    Ulm, 89081, Germany

  • West China Hospital, Sichuan University

    Chengdu, 610041, China

  • Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, 430022, China

  • Yokohama City University Medical Center

    Kanagawa, 232-0024, Japan

  • Zhejiang Cancer Hospital

    Hangzhou, 310022, China

  • Zhongda Hospital Affiliated to Southeast University

    Nanjing, 210009, China

  • Zhongnan Hospital of Wuhan University

    Wuhan, 430071, China

  • Zhongshan Hospital Fudan Unvierstiy

    Shanghai, China

  • Zhujiang Hospital, Southern Medical University

    Guangzhou, 510280, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.